BRAF-MEK Inhibition Is Effective in BRAFV600E-Mutant Papillary Craniopharyngioma
- PMID: 37477404
- DOI: 10.1158/2159-8290.CD-RW2023-116
BRAF-MEK Inhibition Is Effective in BRAFV600E-Mutant Papillary Craniopharyngioma
Abstract
Vemurafenib plus cobimetinib is effective in patients with BRAF-mutant papillary craniopharyngioma.
©2023 American Association for Cancer Research.
Comment on
-
BRAF-MEK Inhibition in Newly Diagnosed Papillary Craniopharyngiomas.N Engl J Med. 2023 Jul 13;389(2):118-126. doi: 10.1056/NEJMoa2213329. N Engl J Med. 2023. PMID: 37437144 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
